QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

NCT04326829 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Tumor

Interventions

DRUG: QL1604

Sponsor

Qilu Pharmaceutical Co., Ltd.